A5013594343- Genetic and Kidney Cyst Diseases
- Renal Diseases and Glomerulopathies
- Biomedical Research and Pathophysiology
- Renal and related cancers
- Electrolyte and hormonal disorders
- Dialysis and Renal Disease Management
- Pediatric Urology and Nephrology Studies
- Ion Transport and Channel Regulation
- Genetic Syndromes and Imprinting
- Cystic Fibrosis Research Advances
- Organ Donation and Transplantation
- Chronic Kidney Disease and Diabetes
- Fetal and Pediatric Neurological Disorders
- Pregnancy and preeclampsia studies
- Renal cell carcinoma treatment
- Parathyroid Disorders and Treatments
- Vascular Malformations and Hemangiomas
- COVID-19 Clinical Research Studies
- Liver Disease Diagnosis and Treatment
- Glycogen Storage Diseases and Myoclonus
- Cerebrospinal fluid and hydrocephalus
- Chronic Lymphocytic Leukemia Research
- Cell Adhesion Molecules Research
- Neurological and metabolic disorders
- Long-Term Effects of COVID-19
University Medical Center Groningen
2016-2025
University of Groningen
2016-2025
Amphia Ziekenhuis
2024
Geneeskundige en Gezondheidsdienst
2022
Dialyse Centrum Groningen
2015-2018
Radboud University Nijmegen
2015
Pediatric Nephrology of Alabama
2014
Kidney Centre
2010
Boston Children's Hospital
2008
Harvard University
2008
Autosomal dominant polycystic kidney disease (ADPKD) is the fourth most common renal requiring replacement therapy (RRT). Still, there are few epidemiological data on prevalence of, and survival RRT for ADPKD. This study used from ERA-EDTA Registry in 12 European countries with 208 million inhabitants. We studied four 5-year periods (1991–2010). Survival analysis was performed by Kaplan–Meier method Cox proportional hazards regression. From first to last period, of ADPKD increased 56.8 91.1...
<h3>Importance</h3> Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation in both kidneys and loss of renal function, eventually leading to a need for replacement therapy. There are limited therapeutic management options. <h3>Objective</h3> To examine the effect somatostatin analogue lanreotide on rate function patients with later-stage ADPKD. <h3>Design, Setting, Participants</h3> An open-label randomized clinical trial blinded end point...
Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent hereditary renal disease, characterized by cyst formation in kidneys leading to end stage failure. It clinically acknowledged that ADPKD patients have impaired urine concentrating capacity, but mechanism behind this observation unknown.Fifteen (estimated GFR ≥60 ml/min per 1.73 m(2)) and 15 age- sex-matched healthy controls underwent a standard prolonged water deprivation test which plasma osmolality, vasopressin,...
Experimental studies suggest a detrimental role for vasopressin in the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). However, it is unknown whether endogenous concentration associated with severity patients ADPKD.Plasma copeptin (a marker levels) was measured 102 ADPKD (diagnosis based on Ravine criteria) by an immunoassay. Plasma and urinary osmolarity were also measured. To assess severity, GFR effective renal blood flow continuous infusion 125I-iothalamate...
BackgroundExperimental studies have suggested that vasopressin plays a detrimental role in autosomal dominant polycystic kidney disease (ADPKD). It is, however, unknown whether endogenous concentration is associated with function decline subjects ADPKD.
In autosomal dominant polycystic kidney disease (ADPKD), there are only scarce data on the effect of salt and protein intake progression. Here we studied association these dietary factors with rate progression in ADPKD what mediating by analyzing an observational cohort 589 patients ADPKD. Salt were estimated from 24-hour urine samples plasma copeptin concentration measured as a surrogate for vasopressin. The annual change glomerular filtration (eGFR) height adjusted total volume (htTKV)...
The vasopressin V2 receptor antagonist tolvaptan is the only drug that has been proven to be nephroprotective in autosomal dominant polycystic kidney disease (ADPKD). Tolvaptan also causes polyuria, limiting tolerability. We hypothesized cotreatment with hydrochlorothiazide or metformin may ameliorate this side effect.
Chronically elevated vasopressin (VP) plasma levels have been shown to induce accelerated renal function decline in rats with chronic failure. Whether endogenous VP is a risk factor humans has not investigated yet. We aimed investigate whether, transplant recipients, concentration associated change during follow-up.In this prospective study, all consecutive patients visiting our kidney outpatient clinic between August 2001 and July 2003 were asked participate. Serum creatinine was assessed...
Background. The variable course of immunoglobulin A nephropathy (IgAN) warrants accurate tools for the prediction progression. Urinary kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) are markers detection early tubular damage caused by various renal conditions. We evaluated prognostic value these in patients with IgAN.
The renoprotective effect of vasopressin V2 receptor antagonist (V2RA) is currently being tested in a clinical trial early autosomal dominant polycystic kidney disease (ADPKD). If efficacious, this warrants life-long treatment with V2RA, however, associated side effects as polydipsia and polyuria. We questioned whether we could reduce the without influencing by starting later or lowering drug dosage.To investigate this, administered V2RA OPC-31260 at high (0.1%) low (0.05%) dose to...
BackgroundThe TEMPO 3:4 Trial results suggested that tolvaptan had no effect compared with placebo on albuminuria in autosomal-dominant polycystic kidney disease (ADPKD) patients. However, the use of categorical 'albuminuria events' may have resulted a loss sensitivity to detect changes. The aim this study is investigate effects as continuous variable.